Eckert & Ziegler Strahlen & Medizintechnik AG provided earnings guidance for the full year of 2015. The sale of the shares in OctreoPharm Sciences GmbH to IPSEN took legal effect June 30, 2015 following the receipt of an initial payment. As a result, the Executive Board of the company has raised its profit forecast for 2015 to at least EUR 2.00 per share, or just over EUR 10 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.84 EUR | -2.10% | -6.86% | +8.57% |
May. 15 | ECKERT & ZIEGLER : Hauck & Aufhauser reiterates its Buy rating | ZD |
May. 14 | Eckert & Ziegler SE Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+8.57% | 1B | |
+1.17% | 7.47B | |
-5.77% | 4.66B | |
-1.19% | 3.1B | |
+10.03% | 2.21B | |
-31.24% | 1.05B | |
+3.00% | 895M | |
-48.27% | 817M | |
-28.39% | 702M | |
-23.88% | 677M |
- Stock Market
- Equities
- EUZ Stock
- News Eckert & Ziegler SE
- Eckert & Ziegler Strahlen & Medizintechnik AG Provides Earnings Guidance for the Full Year of 2015